Educational content on VJOncology is intended for healthcare professionals only. By visiting this website and accessing this information you confirm that you are a healthcare professional.

Share this video  

SABCS 2020 | Next steps in breast cancer: de-escalation & immunotherapy

Roisin Connolly • 11 Dec 2020
SABCS 2020
Breast Cancer Antibodies Paclitaxel Pertuzumab Sacituzumab govitecan Trastuzumab
CompassHER2-pCR

Roisin Connolly, MD, University College Cork, Cork, Ireland, provides a horizon scan of breast cancer care, including an increased focus on de-escalation strategies as evaluated in the ongoing CompassHER2-pCR study (NCT04266249), a Phase II study delineating how well paclitaxel, trastuzumab, and pertuzumab work in eliminating further chemotherapy after surgery in patients with HER2-positive stage II-IIIa breast cancer who have no cancer remaining at surgery after pre-operative chemotherapy and HER2-targeted therapy. This interview was recorded via an online conference call with The Video Journal of Oncology (VJOncology).

More from Roisin Connolly

SABCS highlights: RxPONDER
1:20
SABCS highlights: RxPONDER
Roisin Connolly • 11 Dec 2020
E2112: endocrine therapy plus entinostat in HR+ advanced breast cancer
2:55
E2112: endocrine therapy plus entinostat in HR+ advanced breast cancer
Roisin Connolly • 15 Dec 2020

Related Videos

How will SARMs fit into the current breast cancer treatment paradigm?
1:14
How will SARMs fit into the current breast cancer treatment paradigm?
Rafael Grochot • 2 Jul 2026
Phase I/II trial of vosilasarm and endocrine therapy in AR+/ER+/HER2− breast cancer
1:35
Phase I/II trial of vosilasarm and endocrine therapy in AR+/ER+/HER2− breast cancer
Rafael Grochot • 2 Jul 2026
HYPORT: does the number of fractions of RNRT impact the typical symptoms experienced?
1:07
HYPORT: does the number of fractions of RNRT impact the typical symptoms experienced?
Sanjoy Chatterjee • 17 May 2026
Design and aim of the HYPORT study in regional nodal breast cancer
1:23
Design and aim of the HYPORT study in regional nodal breast cancer
Sanjoy Chatterjee • 17 May 2026

Choose your cookie settings

VJOncology uses necessary cookies to make the site work. With your permission we'd also like to use analytics, preference and marketing cookies to understand how the site is used and improve it.

Choose an option to continue. You can change it at any time on our Cookie Policy page, linked at the bottom of every page.

Cookie Policy (opens in a new tab)
The content of VJOncology is intended for healthcare professionals